Literature DB >> 23026068

Comparative analysis of clinical outcomes in patients with osteoporotic vertebral compression fractures (OVCFs): conservative treatment versus balloon kyphoplasty.

Hwan Mo Lee1, Si Young Park, Soon Hyuck Lee, Seung Woo Suh, Jae Young Hong.   

Abstract

BACKGROUND CONTEXT: Most osteoporotic vertebral compression fractures (OVCFs) can be treated conservatively. Recently, kyphoplasty has become a common treatment for painful osteoporotic compression fractures and has shown numerous benefits, such as early pain control and height restoration of the collapsed vertebral body. In spite of being a simple procedure, numerous complications related to kyphoplasty have been reported. Moreover, there is limited evidence to support its superiority.
PURPOSE: To compare the clinical outcomes of patients with OVCF according to different treatment modalities and identify clinical risk factors related to failure of conservative treatment of OVCF. STUDY
DESIGN: A prospective study consisting of a review of case report forms. PATIENTS SAMPLE: We prospectively enrolled 259 patients who had one or two acute painful OVCFs confirmed by magnetic resonance imaging. All patients were treated conservatively in the initial 3 weeks. Kyphoplasty was performed in 91 patients who complained of sustained back pain and disability in spite of conservative treatment for the initial 3 weeks. OUTCOME MEASURES: Pain score using visual analog scale (VAS) and the Oswestry Disability Index (ODI).
METHODS: Participants were stratified according to age, sex, level and number of fractures, bone mineral density, body mass index (BMI), collapse rates, and history of spine fractures. Pain scores using VASs were assessed at 1 week and at 1, 3, 6, and 12 months.
RESULTS: A total of 259 patients were enrolled, and 231 patients (82 of 91 patients in the kyphoplasty group [KP] and 149 of 168 patients in the conservative treatment group) completed the 1-year follow-up. About 65% of patients were treated successfully with conservative treatment. Risk factors for failure of 3 weeks of conservative treatment were older age (older than 78.5 years), severe osteoporosis (t score less than -2.95), overweight (BMI more than 25.5), and larger collapse rates (more than 28.5%). There were significant reductions in VAS and ODI scores in both groups at each follow-up assessment. At the first month, better clinical results were observed in KP. However, there were no significant differences in outcome measures between the two groups at 3, 6, or 12 months. Thirteen subsequent compression fractures (five in KP and eight in the conservative treatment group) occurred during the 1-year follow-up period.
CONCLUSION: Both treatments of OVCF showed successful clinical results at the end of the 1-year follow-up period. Kyphoplasty showed better outcomes in the first month only. Given these results, prompt kyphoplasty should not be indicated in the case of a patient with OVCF that has no risk factors for failure with conservative treatment. Rather, a trial of conservative, 3-week treatment would be beneficial.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23026068     DOI: 10.1016/j.spinee.2012.08.024

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  33 in total

1.  Can Internet information on vertebroplasty be a reliable means of patient self-education?

Authors:  T Barrett Sullivan; Joshua T Anderson; Uri M Ahn; Nicholas U Ahn
Journal:  Clin Orthop Relat Res       Date:  2013-12-12       Impact factor: 4.176

2.  Vertebral augmentation reduces the 12-month mortality and morbidity in patients with osteoporotic vertebral compression fractures.

Authors:  Roberto Luigi Cazzato; Teodora Bellone; Marco Scardapane; Pierre De Marini; Pierre-Alexis Autrusseau; Pierre Auloge; Julien Garnon; Jack W Jennings; Afshin Gangi
Journal:  Eur Radiol       Date:  2021-04-26       Impact factor: 5.315

3.  Underdiagnosis of osteoporotic vertebral fractures in patients with fragility fractures: retrospective analysis of over 300 patients.

Authors:  Vanna Bottai; Stefano Giannotti; Gloria Raffaetà; Maurizio Mazzantini; Francesco Casella; Gaia De Paola; Agnese Menconi; Francesca Falossi; Giulio Guido
Journal:  Clin Cases Miner Bone Metab       Date:  2016-10-05

4.  Aggravation of spinal cord compromise following new osteoporotic vertebral compression fracture prevented by teriparatide in patients with surgical contraindications.

Authors:  Y Zhao; R Xue; N Shi; Y Xue; Y Zong; W Lin; B Pei; C Sun; R Fan; Y Jiang
Journal:  Osteoporos Int       Date:  2016-05-31       Impact factor: 4.507

Review 5.  Balloon kyphoplasty versus percutaneous vertebroplasty for treatment of osteoporotic vertebral compression fractures (OVCFs).

Authors:  G Zhao; X Liu; F Li
Journal:  Osteoporos Int       Date:  2016-04-27       Impact factor: 4.507

6.  Denosumab Treatment Improves Health-Related Quality of Life in Osteoporosis: Is It Still an Attractive Topic?

Authors:  Antimo Moretti; Giovanni Iolascon
Journal:  JBMR Plus       Date:  2019-09-09

Review 7.  Appropriateness criteria for treatment of osteoporotic vertebral compression fractures.

Authors:  S Luthman; J Widén; F Borgström
Journal:  Osteoporos Int       Date:  2017-12-19       Impact factor: 4.507

8.  Radiographic adjacent segment degeneration and risk factors for osteoporotic vertebral compression fractures treated with percutaneous kyphoplasty.

Authors:  Tianyi Wang; Fangda Si; Lei Zang; Ning Fan; Shuo Yuan; Peng Du; Qichao Wu; Aobo Wang; Xuanyu Lu
Journal:  Int Orthop       Date:  2022-07-22       Impact factor: 3.479

Review 9.  Risks and benefits of percutaneous vertebroplasty or kyphoplasty in the management of osteoporotic vertebral fractures.

Authors:  O Lamy; B Uebelhart; B Aubry-Rozier
Journal:  Osteoporos Int       Date:  2013-11-22       Impact factor: 4.507

10.  Review of Vertebral Augmentation: An Updated Meta-analysis of the Effectiveness.

Authors:  Douglas Beall; Morgan P Lorio; B Min Yun; Maria J Runa; Kevin L Ong; Christopher B Warner
Journal:  Int J Spine Surg       Date:  2018-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.